• Skip to primary navigation
  • Skip to main content
SRI logo
  • About
    • Press room
  • Expertise
    • Advanced imaging systems
    • Artificial intelligence
    • Biomedical R&D services
    • Biomedical sciences
    • Computer vision
    • Cyber & formal methods
    • Education and learning
    • Innovation strategy and policy
    • National security
    • Ocean & space
    • Quantum
    • QED-C
    • Robotics, sensors & devices
    • Speech & natural language
    • Video test & measurement
  • Ventures
  • NSIC
  • Careers
  • Contact
  • 日本支社
Search
Close
Home » Archives for Thomas Kilduff
Thomas Kilduff

Thomas Kilduff

Center Director, Center for Neuroscience
Go to bio page

Publications

Biomedical sciences publications July 9, 2021 Article

Cerebrospinal Fluid Monoamine Levels in Central Disorders of Hypersomnolence

Thomas Kilduff

Whether the cause of daytime sleepiness in narcolepsy type 1 (NT1) is a direct consequence of the loss of orexin (ORX) neurons or whether low orexin reduces the efficacy of the monoaminergic systems to promote wakefulness is unclear.

Biomedical sciences publications June 11, 2021

Animal Models of Narcolepsy and the Hypocretin/orexin System: Past, Present, and Future

Thomas Kilduff

Animal models have advanced not only our understanding of the etiology and phenotype of the sleep disorder narcolepsy but have also informed sleep/wake regulation more generally.

Biomedical sciences publications May 28, 2021

Hypocretin/Orexin Receptor Pharmacology and Sleep Phases

Thomas Kilduff

The involvement of this system in a disorder characterized by the loss of control over arousal state boundaries also suggested its role as a critical component of endogenous sleep-wake regulatory circuitry.

Speech & natural language publications April 21, 2020 Article

Dual orexin and MCH neuron-ablated mice display severe sleep attacks and cataplexy

Thomas Kilduff

Orexin/hypocretin-producing and melanin-concentrating hormone-producing (MCH) neurons are co-extensive in the hypothalamus and project throughout the brain to regulate sleep/wakefulness.

Biomedical sciences publications April 13, 2020

Acute Cognitive Effects of the Hypocretin Receptor Antagonist Almorexant Relative to Zolpidem and Placebo: A Randomized Clinical Trial

Thomas Kilduff

This study aimed to determine whether ALM produces less acute cognitive impairment than ZOL in human subjects.

Biomedical sciences publications March 1, 2020

Shallow Metabolic Depression and Human Spaceflight: A Feasible First Step

Thomas Kilduff

Here, we discuss shallow MD as a feasible first step toward synthetic torpor during spaceflight and summarize perspectives following a recent NASA-hosted workshop.

Biomedical sciences publications September 13, 2019 Article

REM Sleep-Active MCH Neurons Are Involved in Forgetting Hippocampus-Dependent Memories

Thomas Kilduff

Melanin concentrating hormone-producing neurons (MCH neurons) in the hypothalamus actively contribute to forgetting in rapid eye movement (REM) sleep.

Biomedical sciences publications July 13, 2019 Article

Trace Amine-Associated Receptor 1 Agonism Promotes Wakefulness Without Impairment of Cognition in Cynomolgus Macaques

Thomas Kilduff

Trace amine-associated receptor 1 (TAAR1) is a G-protein coupled receptor with affinity for the trace amines. TAAR1 agonists have pro-cognitive, antidepressant-, and antipsychotic-like properties in both rodents and non-human primates (NHPs). TAAR1 agonism also increases wakefulness and suppresses rapid-eye movement (REM) sleep in mice and rats and reduces cataplexy in two mouse models of narcolepsy. We investigated the effects of TAAR1 agonism in Cynomolgus macaques, a diurnal species that exhibits consolidated night-time sleep, and evaluated the effects of TAAR1 agonists on cognition using a working memory (WM) paradigm in this species. Adult male Cynomolgus macaques (n = 6) were surgically implanted to record the electroencephalogram (EEG), electromyogram, and locomotor activity (LMA) and the efficacy of the TAAR1 partial agonist RO5263397 (0.1,1,10 mg/kg, p.o.) on sleep/wake, EEG spectra, and LMA was determined. In a second experiment, the acute effects of RO5263397 (0.1,1,10 mg/kg, p.o.) were assessed on a delayed-match-to-sample test of WM in adult male macaques (n = 7). RO5263397 (10 mg/kg) administered at lights off, when sleep pressure was high, promoted wakefulness and reduced both REM and non-REM sleep without inducing hyperlocomotion. RO5263397 (10 mg/kg) also increased delta/theta activity during all vigilance states. RO5263397 had no effect on WM at either short (2 sec) or long (10 sec) delay intervals. The wake-enhancing and REM-suppressing effects of R05263397 shown here in a diurnal primate are consistent with previous results in nocturnal rodents. These effects and the associated alterations in EEG spectra occurred without inducing hyperlocomotion or affecting WM, encouraging further study of TAAR1 agonists as potential narcolepsy therapeutics.

Biomedical sciences publications March 13, 2019 Article

Excitation of Cortical nNOS/NK1R Neurons by Hypocretin 1 Is Independent of Sleep Homeostasis

Thomas Kilduff

We have proposed that cortical nNOS/NK1R interneurons have a role in sleep homeostasis.

  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Interim pages omitted …
  • Go to page 7
  • Go to Next Page »

How can we help?

Once you hit send…

We’ll match your inquiry to the person who can best help you.

Expect a response within 48 hours.

Career call to action image

Make your own mark.

Search jobs

Our work

Case studies

Publications

Timeline of innovation

Areas of expertise

Institute

Leadership

Press room

Media inquiries

Compliance

Careers

Job listings

Contact

SRI Ventures

Our locations

Headquarters

333 Ravenswood Ave
Menlo Park, CA 94025 USA

+1 (650) 859-2000

Subscribe to our newsletter


日本支社
SRI International
  • Contact us
  • Privacy Policy
  • Cookies
  • DMCA
  • Copyright © 2022 SRI International